Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37.1Revenue $M0.3Net Margin (%)--Altman Z-Score12.0
Enterprise Value $M-1.7EPS $-2.3Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.6Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %-52.5Quick Ratio25.9Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-46.2Current Ratio25.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-36.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-38.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.1ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ABIO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABIOFirst Eagle Investment 2010-03-31 Sold Out -0.01%$110.88 - $345.24
($133.67)
$ 4.10-97%Sold Out0
ABIOFirst Eagle Investment 2009-12-31 Reduce-0.01%$94.5 - $181.44
($126.85)
$ 4.10-97%Reduce -27.96%9,817
ABIOFirst Eagle Investment 2009-09-30 Add0.01%$95.76 - $184.8
($145.77)
$ 4.10-97%Add 62.38%13,627
ABIOFirst Eagle Investment 2009-06-30 Add$108.36 - $564.9
($288.66)
$ 4.10-99%Add 24.34%8,392
ABIOFirst Eagle Investment 2009-03-31 Buy 0.02%$163.8 - $275.86
($220.96)
$ 4.10-98%New holding6,749
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABIO is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ABIO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BRISTOW MICHAEL RSee Remarks 2016-04-05Sell724$3.5216.48view
Ozeroff Christopher DavidS.V.P., General Counsel 2016-04-05Sell366$3.5216.48view
Keuer Thomas ACOO 2016-04-05Sell384$3.5216.48view
Selby Brian L.VP, Finance 2016-04-04Sell1,114$3.5216.48view
Keuer Thomas ACOO 2016-03-01Sell457$3.5316.15view
Ozeroff Christopher DavidS.V.P., General Counsel 2016-03-01Sell458$3.5116.81view
BRISTOW MICHAEL RSee Remarks 2016-03-01Sell752$3.517.14view
Selby Brian L.VP, Finance 2016-02-29Sell160$3.4618.5view
Keuer Thomas ACOO 2015-10-16Sell496$5.14-20.23view
Selby Brian L.VP, Finance 2015-09-18Sell476$6.23-34.19view

Quarterly/Annual Reports about ABIO:

News about ABIO:

Articles On GuruFocus.com
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 15 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) May 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 16 2009 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) May 15 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) Feb 07 2009 

More From Other Websites
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 18 2016
ARCA biopharma Announces 75th Patient Enrolled in Genetic-AF Phase 2B/3 Clinical Trial Apr 18 2016
ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial Apr 18 2016
ARCA BIOPHARMA, INC. Financials Mar 23 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 17 2016
ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update Mar 17 2016
ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report Mar 17 2016
Bearish case for Valeant Mar 17 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 07 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 16 2016
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 12 2016
GENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient Jan 12 2016
Applying Lessons from KBIO Dec 08 2015
2 Micro-Cap Opportunities in Atrial Fibrillation Nov 30 2015
Biotechs Under 20 Dollars Poised to Breakout Nov 23 2015
ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference Nov 19 2015
2 Important Takeaways from ARCA Biopharma's Q3 Results Nov 18 2015
ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update Nov 12 2015
ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 12 2015
ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update Nov 12 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)